Phase 3 Hemoglobin Clinical Trials
7 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
Paroxysmal nocturnal hemoglobinuria
Regeneron Pharmaceuticals35 enrolled8 locationsNCT07154745
Recruiting
Phase 3
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Paroxysmal Nocturnal Hemoglobinuria, PNH
Novartis Pharmaceuticals12 enrolled13 locationsNCT06934967
Recruiting
Phase 3
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Beta-ThalassemiaSickle Cell DiseaseHematologic Diseases+4 more
Vertex Pharmaceuticals Incorporated26 enrolled6 locationsNCT05477563
Recruiting
Phase 3
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
Paroxysmal nocturnal hemoglobinuria
Regeneron Pharmaceuticals202 enrolled43 locationsNCT05744921
Recruiting
Phase 3
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
PNHExtravascular HemolysisParoxysmal nocturnal hemoglobinuria
Alexion Pharmaceuticals, Inc.6 enrolled4 locationsNCT06449001
Recruiting
Phase 3
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Paroxysmal nocturnal hemoglobinuria
Wuhan Createrna Science and Technology Co., Ltd20 enrolled1 locationNCT06932471
Recruiting
Phase 2Phase 3
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria, PNH
Wuhan Createrna Science and Technology Co., Ltd120 enrolled1 locationNCT06933914